How Putnam’s CEO Matt Riordan Is Accelerating Cancer Therapy Adoption | ASCO 2025 Highlights

Описание: At ASCO 2025, Matt Riordan, CEO of Putnam Associates, part of Inizio Advisory, shares expert insights on the future of cancer treatment, commercialization strategy, and accelerating the adoption of next-gen therapies across clinical settings.

🔑 Highlights

✅ Key challenge: ensuring adoption across both academic and community oncology
✅ Faster clinician and patient education = faster uptake of breakthrough drugs
✅ Real-world strategy behind the launch of the first CAR-T therapy
✅ AI in oncology: overhyped or underutilized? Why human judgment still matters
✅ Aligning medical, commercial, and access teams around a unified strategy
✅ Inizio’s integrated approach: turning strategy into action across the lifecycle
✅ Why the real win is accelerating access for patients—without delay

This episode is sponsored by Inizio.

#ASCO2025 #PutnamAssociates #InizioAdvisory #OncologyStrategy #CancerInnovation #CAR_T #RadioligandTherapy

SUBSCRIBE to get the latest #oncodaily    / @oncodailytv  

Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn:   / oncodaily  
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram:   / oncodailynews  
Follow OncoDaily on TikTok:   / oncodaily  
Like OncoDaily on Facebook:   / oncodaily  

SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter

About OncoDaily
OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information.

Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research.

🔔 New videos every day!
💻 Visit us at https://oncodaily.com/